Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
Titel:
Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
Auteur:
Zhou, T. Yang, Y. Ma, S. Lin, L. Zhou, T. Zhang, C. Ding, X. Wang, R. Feng, G. Chen, Y. Xu, R. Huang, Y. Zhang, L.